Traditional and Novel Tools for Diagnosis of Acute Kidney Injury

Tohme, Fadi A.; Kellum, John A.

doi:10.1007/978-3-030-26710-0_45

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novel damage biomarkers are the neutrophil gelatinase-associated lipocalin (NGAL) and the kidney injury molecule 1 (KIM-1), whereas the insulin-like growth factor binding protein 7 (IGFBP-7) and tissue inhibitor of metalloproteinase-2 (TIMP-2) belong to the novel stress biomarkers. These biomarkers may predict the detection of AKI, but their clinical application is still uncertain [ 68 , 69 ]. A combo of urinary TIMP-2 and IGFBP-7 called as nephron-check has been recognized by the FDA for the diagnosis of AKI [ 70 ].…”

Section: Resultsmentioning

confidence: 99%

Plants with Therapeutic Potential for Ischemic Acute Kidney Injury: A Systematic Review

Ali

Sampaio

Khan

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a complex condition which has an intricate pathology mostly involving hemodynamic, inflammatory, and direct toxic effects at the cellular level with high morbidity and mortality ratios. Renal ischemic reperfusion injury (RIRI) is the main factor responsible for AKI, most often observed in different types of shock, kidney transplantation, sepsis, and postoperative procedures. The RIRI-induced AKI is accompanied by increased reactive oxygen species generation together with the activation of various inflammatory pathways. In this context, plant-derived medicines have shown encouraging nephroprotective properties. Evidence provided in this systemic review leads to the conclusion that plant-derived extracts and compounds exhibit nephroprotective action against renal ischemic reperfusion induced-AKI by increasing endogenous antioxidants and decreasing anti-inflammatory cytokines. However, there is no defined biomarker or target which can be used for treating AKI completely. These plant-derived extracts and compounds are only tested in selected transgenic animal models. To develop the results obtained into a therapeutic entity, one should apply them in proper vertebrate multitransgenic animal models prior to further validation in humans.

show abstract

Section: Resultsmentioning

confidence: 99%